Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes

Biochemical Pharmacology

Volumn 75, Issue 6, 2008, Pages 1426-1437

  Quintieri, Luigi ^a   Palatini, Pietro ^a   Nassi, Alberto ^a   Ruzza, Paolo ^b   Floreani, Maura ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

Author keywords

CYP3A enzymes; Flavones; Flavonoid drug interaction; Human liver microsomes; Midazolam

Indexed keywords

CHRYSIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIOSMETIN; FLAVONE; FLAVONOID; HYDROXYL GROUP; LUTEOLIN; MIDAZOLAM; RECOMBINANT ENZYME; SALVIGENIN; TANGERETIN;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME METABOLISM; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FLAVONOIDS; HUMANS; LUTEOLIN; MICROSOMES, LIVER; MIDAZOLAM; RECOMBINANT PROTEINS;

EID: 39749180482     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.11.012     Document Type: Article

References (50)

1. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34 (2002) 83-448
2. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol 39 (1999) 1-17
3. Huang W., Lin Y.S., McConn II D.J., Calamia J.C., Totah R.A., Isoherranen N., et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32 (2004) 1434-1445
4. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
5. Lin Y.S., Dowling A.L., Quigley S.D., Farin F.M., Zhang J., Lamba J., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62 (2002) 162-172
6. Beecher G.R. Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 133 (2003) 3248S-3254S
7. Sparreboom A., Cox M.C., Acharya M.R., and Figg W.D. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22 (2004) 2489-2503
8. Middleton Jr. E., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52 (2000) 673-751
9. Havsteen B.H. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96 (2002) 67-202
10. Rice-Evans C.A., Miller N.J., and Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 20 (1996) 933-956
11. Hodek P., Trefil P., and Stiborová M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 139 (2002) 1-21
12. Williams R.J., Spencer J.P.E., and Rice-Evans C. Flavonoids: antioxidants or signalling molecules?. Free Radic Biol Med 36 (2004) 838-849
13. Moon Y.J., Wang X., and Morris M.E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 20 (2006) 187-210
14. Gonzalez F.J., and Gelboin H.V. Role of human cytochrome P-450s in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26 (1994) 165-183
15. Doostdar H., Burke M.D., and Mayer R.T. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144 (2000) 31-38
16. Siess M.H., Leclerc J., Canivenc-Lavier M.C., Rat P., and Suschetet M. Heterogenous effects of natural flavonoids on monooxygenase activities in human and rat liver microsomes. Toxicol Appl Pharmacol 130 (1995) 73-78
17. Mäenpää J., Hall S.D., Ring B.J., Strom S.C., and Wrighton S.A. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8 (1998) 137-155
18. Backman J.T., Mäenpää J., Belle D.J., Wrighton S.A., Kivistö K.T., and Neuvonen P.J. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerin juice on midazolam hydroxylation. Clin Pharmacol Ther 67 (2000) 382-390
19. Bailey D.G., and Dresser G.K. Interaction between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 4 (2004) 281-297
20. Bressler R. Grapefruit juice and drug interaction. exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics 61 (2006) 12-18
21. Schmiedlin-Ren P., Edwards D.J., Fitzsimmons M.E., He K., Lown K.S., Woster P.M., et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25 (1997) 1228-1233
22. Evans A.M. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 22 (2000) 131-136
23. Ho P.C., Saville D.J., and Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 4 (2001) 217-227
24. Lu Y., and Foo L.Y. Polyphenolics of Salvia-a review. Phytochemistry 59 (2002) 117-140
25. Lima C.F., Valentao P.C., Andrade P.B., Seabra R.M., Fernandes-Ferreira M., and Pereira-Wilson C. Water and methanolic extracts of Salvia officinalis protect HepG2 cells from t-BHP induced oxidative damage. Chem Biol Interact 167 (2007) 107-115
26. Cova D., De Angelis L., Giavarini F., Palladini G., and Perego R. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 30 (1992) 29-33
27. Lyseng-Williamson K.A., and Perry C.M. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 63 (2003) 71-100
28. Bergan J.J. Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg. Angiology 56 Suppl. 1 (2005) S21-S24
29. Rajnarayana K., Reddy M.S., and Krishna D.R. Diosmin pretreatment affects bioavailability of metronidazole. Eur J Clin Pharmacol 58 (2003) 803-807
30. Kenworthy K.E., Bloomer J.C., Clarke S.E., and Houston J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48 (1999) 716-727
31. Fabre G., Rahmani R., Placidi M., Combalbert J., Covo J., Cano J.P., et al. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol 37 (1988) 4389-4397
32. Kronbach T., Mathys D., Umeno M., Gonzales F.J., and Meyer U.A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36 (1989) 89-96
33. Wrighton S.A., and Ring B.J. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 11 (1994) 921-924
34. Venkatakrishnan K., Von Moltke L.L., and Greenblatt D.J. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41 (2001) 1149-1179
35. Palatini P. A simple method for discriminating between full and partial inhibitors. Biochem Int 16 (1988) 359-368
36. Segel J.H. Enzyme kinetics (1975), John Wiley & Sons
37. von Moltke L.L., Greenblatt D.J., Schmider J., Duan S.X., Wright C.E., Hramatz J.S., et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36 (1996) 783-791
38. Ghosal A., Satoh H., Thomas P.E., Bush E., and Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24 (1996) 940-947
39. Ito K., Ogihara K., Kanamitsu S.I., and Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31 (2003) 945-954
40. Patki K.C., von Moltke L.L., and Greenbblatt D.J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos 31 (2003) 938-944
41. Emoto C., and Iwasaki K. Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 36 (2006) 219-233
42. Williams J.A., Ring B.J., Cantrell V.A., Jones D.R., Eckstein J.J., Ruterbories K., et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30 (2002) 883-891
43. Wrighton S.A., and Stevens J.C. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22 (1992) 1-21
44. i values and impact of CYP3A5 expression. Drug Metab Dispos 27 (1999) 180-187
45. Khan K.K., He Y.Q., Domanski T.L., and Halpert J.R. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61 (2002) 495-506
46. Lown K.S., Ghosh M., and Watkins P.B. Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metab Dispos 26 (1998) 185-187
47. Zhou S., Gao Y., Jiang W., Huang M., Xu A., and Paxton J.W. Interactions of herbs with cytochrome P450. Drug Metab Rev 35 (2003) 35-98
48. Schlupper D., Giesa S., and Gebhardt R. Influence of biotransformation of luteolin, luteolin 7-O-glucoside, 3′,4′-dihydroxyflavone and apigenin by cultured rat hepatocytes on antioxidative capacity and inhibition of EGF receptor tyrosine kinase activity. Planta Med 72 (2006) 596-603
49. Boutin J.A., Meunier F., Lambert P.H., Hennig P., Bertin D., Serkiz B., et al. In vivo and in vitro glucuronidation of the flavonoid diosmetin in rats. Drug Metab Dispos 21 (1993) 1157-1166
50. van Zanden J.J., van der Woude H., Vaessen J., Usta M., Wortelboer H.M., Cnubben N.H.P., et al. The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem Pharmacol 74 (2007) 345-351